Dendritic cells (DCs) are peripheral blood and bone marrow derived antigen-presenting cells responsible for the initiation of immune responses. Because dendritic cells are clinically well tolerated, it makes them interesting candidates for anti-tumor or antileukemic strategies. The aim of this study was to generate dendritic cell vaccine (DC vaccine) expressing leukemic antigens by differentiating dendritic cells from myeloid blasts of chronicmyeloid leukemia patients to boost their immune system and improve their clinical outcome. Two groups of CML patients were studied and both were given the same chemotherapeutic regimen. Only one of them was also given the DC vaccine as an adjuvant therapy. The dendritic cells were identified morphologically and their maturity was assessed by immunophenotyping them using CD83. The clinical response was evaluated by monitoring any clinical changes in the patients before and after vaccination, and the immune response was monitored by measuring the percentage of CD8 before and after vaccination. There was some improvement both clinically and immunologically indicating that the DC vaccine may be an effective adjuvant therapy.